It would be therefore impossible to apply the platform to identify novel genes associated with the process of differentiation; for that application, the genome-scale microarray platforms (e.g., Affymetrix) are clearly superior.
However, individual microarray platforms themselves differ substantially [ 42] and a multiplatform approach, as used here, clearly defines a robust DTET seen by every technology.
Clearly, the time is ripe to set up studies to formally compare the major microarray platforms that are being used to provide screening analysis data to the wide biomedical community.
There are two major microarray platforms that have been widely used: cDNA microarrays and oligonucleotide microarrays.
Tan, P. K. et al. Evaluation of gene expression measurements from commercial microarray platforms.
Tan, P.K. et al. Evaluation of gene expression measurements from commercial microarray platforms.
Hester, S.D. et al. Comparison of comparative genomic hybridization technologies across microarray platforms.
The US Food and Drug Administration (FDA -led community-wide Microarray Quality Control (MAQC) study generates a large amount oFDA -ledrray data with implementation of ERCs across several commercial microarray platforMicroarray
The technical reproducibility of microarray platforms is well established.
Agilent 8x60K microarray platforms were used for these transcriptome analyses (Xuan et al. 2013).
